Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

NCT01968265 ↗

Phase 2 Completed 38 enrolled Ionis Pharmaceuticals, Inc.

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCCRRx in combination with metformin versus placebo + metformin

Timeline

Start: 2013-10
Primary completion: 2015-01
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ISIS-GCCRRx	Antisense oligonucleotide	—	Subcutaneous

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Summary

Timeline

Drugs

Indications